Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Toronto - Delayed Quote CAD

Resverlogix Corp. (RVX.TO)

Compare
0.0500
0.0000
(0.00%)
At close: March 17 at 12:27:30 PM EDT
Loading Chart for RVX.TO
  • Previous Close 0.0500
  • Open 0.0500
  • Bid 0.0450 x --
  • Ask 0.0500 x --
  • Day's Range 0.0500 - 0.0500
  • 52 Week Range 0.0400 - 0.1000
  • Volume 1,000
  • Avg. Volume 46,364
  • Market Cap (intraday) 14.032M
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date Mar 28, 2025 - Apr 5, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.

www.resverlogix.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RVX.TO

View More

Performance Overview: RVX.TO

Trailing total returns as of 3/18/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

RVX.TO
16.67%
S&P/TSX Composite index (^GSPTSE)
0.35%

1-Year Return

RVX.TO
16.67%
S&P/TSX Composite index (^GSPTSE)
13.14%

3-Year Return

RVX.TO
89.80%
S&P/TSX Composite index (^GSPTSE)
13.23%

5-Year Return

RVX.TO
94.51%
S&P/TSX Composite index (^GSPTSE)
110.78%

Compare To: RVX.TO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RVX.TO

View More

Valuation Measures

As of 3/17/2025
  • Market Cap

    14.03M

  • Enterprise Value

    26.83M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.37%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -11.23M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    43k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    901.12k

Research Analysis: RVX.TO

View More

People Also Watch